Pharyngeal cancer stage III represents a significant point in the disease where treatment decisions become more complex, requiring a careful balance between removing cancer, preserving function, and maintaining quality of life.

Understanding Your Treatment Path

When someone receives a diagnosis of stage III pharyngeal cancer, the journey ahead involves making important decisions about treatment. At this stage, the cancer has grown larger than 4 centimeters or has spread to one lymph node on the same side of the neck as the tumor, but the lymph node remains smaller than 3 centimeters. The cancer may also have reached nearby structures like the epiglottis, which is the flap of tissue that helps close the voice box when swallowing.^[1]

The main goal of treating stage III pharyngeal cancer is to eliminate the disease while preserving as much normal function as possible. This includes maintaining the ability to speak clearly, swallow food and liquids safely, and breathe without difficulty. Treatment choices depend on several factors, including where exactly the cancer is located in the throat, how far it has spread, the patient’s overall health, and what side effects might occur with different approaches.^[5]

Healthcare providers work together as a team to create a personalized treatment plan. This team typically includes surgeons who specialize in head and neck operations, doctors who provide radiation therapy and chemotherapy, speech and language therapists, dietitians, and nurses with special training in caring for people with throat cancer. Each member plays a vital role in supporting patients through treatment and recovery.^[19]

Standard Treatment Approaches

For stage III pharyngeal cancer, there are several established treatment methods that medical societies and guidelines recommend based on years of research and clinical experience. The choice between these approaches often depends on whether the cancer has made it difficult to swallow or breathe, as well as the specific location of the tumor within the throat.^[5]

Surgery

Surgery remains one of the main treatment options for stage III pharyngeal cancer. The surgical approach aims to remove the tumor along with a margin of healthy tissue around it to ensure all cancer cells are eliminated. When cancer has made it difficult to swallow or breathe, surgery often becomes the primary treatment choice because it can quickly relieve these symptoms.^[5]

The most common surgical procedure is called a laryngopharyngectomy, which involves removing part or all of the voice box (larynx), part or all of the throat (pharynx), and sometimes a portion of the esophagus. This surgery is typically combined with a neck dissection, where surgeons remove lymph nodes in the neck that may contain cancer cells. The extent of surgery depends on how far the cancer has spread and which structures are affected.^[5]

After this type of surgery, additional procedures are often necessary to help with breathing and nutrition. Surgeons may place a breathing tube called a tracheostomy through the front of the neck to ensure patients can breathe properly. They may also insert a feeding tube, usually through the abdominal wall directly into the stomach (called a gastrostomy), to make sure patients receive adequate nutrition while healing and adjusting to changes in their swallowing ability.^[5]

Surgery for pharyngeal cancer can significantly affect appearance and function. Because of this, reconstructive surgery is often performed at the same time as cancer removal. Plastic surgeons or specialized head and neck surgeons work to rebuild the affected areas, helping to restore both appearance and function as much as possible. The goal is to allow patients to return to eating, speaking, and living as normally as possible after treatment.^[5]

Chemoradiation

Chemoradiation is another primary treatment approach for stage III pharyngeal cancer. This method combines chemotherapy and radiation therapy, giving them at the same time rather than one after the other. The chemotherapy drugs make the cancer cells more sensitive to radiation, which makes the radiation more effective at destroying them.^[5]

For stage III pharyngeal cancer, the most commonly used chemotherapy drug is cisplatin. This medication belongs to a class of drugs called platinum compounds, which work by damaging the DNA inside cancer cells and preventing them from dividing and growing. Cisplatin is given through a vein while radiation is being delivered to the tumor and to lymph nodes on both sides of the neck.^[5]

Chemoradiation offers an important advantage: it may allow patients to keep their voice box and maintain more normal speaking and swallowing abilities compared to surgery. However, if cancer returns after chemoradiation, surgery becomes necessary because the same area cannot be treated with radiation again. This follow-up surgery is called salvage surgery.^[17]

The side effects of chemoradiation can be significant. Patients often experience sore throat, difficulty swallowing, mouth sores, changes in taste, dry mouth, fatigue, and skin changes where radiation is applied. The chemotherapy can cause nausea, vomiting, kidney problems, hearing changes, and a drop in blood cell counts that can increase infection risk. Most of these side effects improve after treatment ends, but some, like dry mouth and swallowing difficulties, may persist long-term.^[5]

Radiation Therapy

External radiation therapy uses high-energy beams directed from outside the body to kill cancer cells. For stage III pharyngeal cancer, radiation is usually given as part of chemoradiation rather than alone, because combining it with chemotherapy improves results. Radiation may also be given after surgery to kill any remaining cancer cells and reduce the chance of the cancer coming back.^[5]

A specialized type of radiation called intensity-modulated radiation therapy (IMRT) is often used for pharyngeal cancer. This advanced technique allows doctors to shape the radiation beams very precisely to match the tumor’s outline. IMRT can deliver higher doses to the cancer while reducing exposure to nearby healthy tissues like salivary glands, the voice box, and the spinal cord. This precision helps reduce side effects and protect important structures.^[5]

Radiation treatment typically continues over several weeks, with patients receiving treatment five days per week. Each session lasts only a few minutes, though preparation and positioning take additional time. The effects of radiation build up over time, meaning side effects often become more noticeable as treatment progresses and may continue for several weeks after treatment ends.^[5]

Chemotherapy Before Other Treatments

Sometimes chemotherapy is given before surgery or radiation therapy with the goal of shrinking the tumor. This approach, called neoadjuvant chemotherapy or induction chemotherapy, can make surgery easier or reduce the amount of radiation needed. The most common drug combination used includes cisplatin and a drug called fluorouracil (also known as 5-fluorouracil or 5-FU).^[5]

Fluorouracil works differently from cisplatin. It interferes with the production of DNA and RNA, which cancer cells need to grow and divide. By blocking these processes, fluorouracil prevents cancer cells from multiplying. When combined with cisplatin, these two drugs attack cancer cells through different mechanisms, which can be more effective than using either drug alone.^[5]

The decision to use chemotherapy before other treatments depends on the tumor’s size and location, as well as the patient’s overall health. Doctors evaluate how well the tumor responds to this initial chemotherapy, and this response can help guide decisions about the best subsequent treatment approach.^[5]

Emerging Treatments in Clinical Trials

While standard treatments have helped many people with stage III pharyngeal cancer, researchers continue to develop and test new therapies that may offer better outcomes or fewer side effects. Clinical trials are research studies that test these promising new approaches before they become widely available. Participating in a clinical trial gives patients access to cutting-edge treatments while helping advance medical knowledge for future patients.^[5]

Immunotherapy

One of the most promising areas of research for stage III pharyngeal cancer involves immunotherapy, which helps the body’s own immune system recognize and attack cancer cells. Cancer cells often develop ways to hide from the immune system or turn off immune responses. Immunotherapy drugs work by blocking these hiding mechanisms, allowing immune cells to find and destroy cancer.^[5]

A drug called pembrolizumab (brand name Keytruda) is being tested for locally advanced pharyngeal cancer, which includes stage III disease. Pembrolizumab belongs to a class of drugs called checkpoint inhibitors. It blocks a protein called PD-1 on immune cells, which normally acts like a brake pedal on the immune system. By blocking PD-1, pembrolizumab releases this brake, allowing immune cells to attack cancer more effectively.^[5]

In clinical trials, pembrolizumab is being given at different points during treatment. Some studies give it before surgery to shrink tumors and make them easier to remove. It is then continued along with radiation therapy (with or without cisplatin chemotherapy), and after radiation finishes, patients continue receiving pembrolizumab alone for a period of time. This multi-phase approach aims to attack the cancer from different angles throughout the treatment process.^[5]

Immunotherapy drugs work differently from chemotherapy and cause different side effects. Instead of directly killing cells, they stimulate the immune system, which can sometimes cause the immune system to attack healthy tissues. Side effects may include fatigue, skin rashes, diarrhea, and in some cases, inflammation of organs like the lungs, liver, or intestines. While these side effects can be serious, they often respond well to treatment with steroids or other immune-suppressing medications.^[5]

Targeted Therapy for HPV-Related Cancer

Many cases of pharyngeal cancer are caused by the human papillomavirus (HPV). These HPV-related cancers often respond better to treatment than cancers caused by tobacco and alcohol. Researchers are investigating whether HPV-positive stage III pharyngeal cancer can be treated with less intensive approaches that might cause fewer long-term side effects while still curing the disease.^[1]

Clinical trials are testing whether patients with HPV-positive tumors can receive lower doses of radiation or less intense chemotherapy combinations while maintaining the same cure rates. The rationale is that because these cancers are generally more sensitive to treatment, reducing treatment intensity might reduce side effects like dry mouth, difficulty swallowing, and hearing loss without compromising survival. These studies are still ongoing, and results will help determine whether treatment can be safely reduced for certain patients.^[1]

Trial Phases and What They Mean

Clinical trials for pharyngeal cancer treatment follow a structured process divided into different phases. Phase I trials are the first studies in humans and focus primarily on safety. They determine the appropriate dose of a new drug and identify what side effects occur. These trials typically involve small numbers of patients.^[5]

Phase II trials continue to evaluate safety but also begin to assess whether the treatment actually works against cancer. These studies enroll more patients and measure how many tumors shrink or disappear, how long responses last, and whether side effects remain manageable. Phase II trials provide the first real evidence of whether a new treatment might be helpful.^[5]

Phase III trials are large studies that compare a new treatment directly against the current standard treatment. These trials involve hundreds or even thousands of patients and are designed to definitively determine whether the new approach is better than, equal to, or worse than existing treatments. Positive results from Phase III trials often lead to approval of new treatments by regulatory agencies.^[5]

Clinical trials for pharyngeal cancer are conducted at major cancer centers throughout North America, Europe, and other regions worldwide. Many trials specifically recruit patients with stage III disease because this represents a group where both cure and quality of life are important goals. Patients interested in clinical trials should discuss options with their healthcare team, who can provide information about available studies and help with the enrollment process.^[5]

Most common treatment methods

• Surgery
  • Laryngopharyngectomy to remove part or all of the voice box, throat, and sometimes part of the esophagus
  • Neck dissection to remove lymph nodes in the neck that may contain cancer
  • Tracheostomy placement to create an opening for breathing
  • Gastrostomy tube placement to provide nutrition during recovery
  • Reconstructive surgery to restore appearance and function of the mouth and neck
  • Salvage surgery if cancer returns after radiation therapy
• Chemoradiation
  • Cisplatin chemotherapy given during the same time period as radiation therapy
  • Radiation delivered to the tumor and lymph nodes on both sides of the neck
  • Combined approach makes radiation more effective at destroying cancer cells
• Radiation Therapy
  • External radiation therapy using high-energy beams from outside the body
  • Intensity-modulated radiation therapy (IMRT) to precisely target tumors while protecting healthy tissue
  • Given after surgery to eliminate remaining cancer cells
  • Treatment typically continues over several weeks with daily sessions
• Chemotherapy
  • Cisplatin to damage DNA in cancer cells and prevent them from dividing
  • Fluorouracil (5-FU) to interfere with DNA and RNA production in cancer cells
  • Combination therapy using both cisplatin and fluorouracil
  • May be given before surgery or radiation to shrink tumors
• Immunotherapy
  • Pembrolizumab (Keytruda) to help the immune system recognize and attack cancer cells
  • Blocks PD-1 protein to release the “brake” on immune system activity
  • May be given before surgery, with radiation therapy, and continued after radiation finishes
  • Being tested in clinical trials for locally advanced pharyngeal cancer